Repeated polysomnography and multiple sleep latency test in narcolepsy type 1 and other hypersomnolence disorders
- PMID: 37544279
- DOI: 10.1016/j.sleep.2023.07.029
Repeated polysomnography and multiple sleep latency test in narcolepsy type 1 and other hypersomnolence disorders
Abstract
Background: The diagnosis of narcolepsy is based on clinical information, combined with polysomnography (PSG) and the Multiple Sleep Latency Test (MSLT). PSG and the MSLT are moderately reliable at diagnosing narcolepsy type 1 (NT1) but unreliable for diagnosing narcolepsy type 2 (NT2). This is a problem, especially given the increased risk of a false-positive MSLT in the context of circadian misalignment or sleep deprivation, both of which commonly occur in the general population.
Aim: We aimed to clarify the accuracy of PSG/MSLT testing in diagnosing NT1 versus controls without sleep disorders. Repeatability and reliability of PSG/MSLT testing and temporal changes in clinical findings of patients with NT1 versus patients with hypersomnolence with normal hypocretin-1 were compared.
Method: 84 patients with NT1 and 100 patients with non-NT1-hypersomnolence disorders, all with congruent cerebrospinal fluid hypocretin-1 (CSF-hcrt-1) levels, were included. Twenty-five of the 84 NT1 patients and all the hypersomnolence disorder patients underwent a follow-up evaluation consisting of clinical assessment, PSG, and a modified MSLT. An additional 68 controls with no sleep disorders were assessed at baseline.
Conclusion: Confirming results from previous studies, we found that PSG and our modified MSLT accurately and reliably diagnosed hypocretin-deficient NT1 (accuracy = 0.88, reliability = 0.80). Patients with NT1 had stable clinical and electrophysiological presentations over time that suggested a stable phenotype. In contrast, the PSG/MSLT results of patients with hypersomnolence, and normal CSF-hcrt-1 had poor reliability (0.32) and low repeatability.
Keywords: Diagnostic validity; Electrophysiology; Hypocretin-1; Narcolepsy; Reliability.
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest Dr. Mignot reports non-financial support from Idorsia Pharmaceuticals Ltd, and personal fees from Jazz Pharmaceuticals, Alairion, ALPCO, INEXIA, Merck, Orexia, Dreem, and Sunovion during the course of the study. Dr. Kornum is a founder of Ceremedy and reports personal fees from Orexia Therapeutics and Novartis. Dr. Torstensen, Dr. Barloese, Dr. Jennum, and Dr. Wanscher have nothing to disclose.
Similar articles
-
Test-Retest Reliability of the Multiple Sleep Latency Test in Central Disorders of Hypersomnolence.Sleep. 2017 Dec 1;40(12). doi: 10.1093/sleep/zsx164. Sleep. 2017. PMID: 29099966
-
Multiple sleep latency test and polysomnography in patients with central disorders of hypersomnolence.Sleep Med. 2021 Mar;79:6-10. doi: 10.1016/j.sleep.2020.12.037. Epub 2021 Jan 2. Sleep Med. 2021. PMID: 33453460
-
Differential characteristics of repeated polysomnography and multiple sleep latency test parameters in narcolepsy type 1 and type 2 patients: a longitudinal retrospective study.Sleep Breath. 2022 Dec;26(4):1939-1946. doi: 10.1007/s11325-021-02525-7. Epub 2021 Nov 25. Sleep Breath. 2022. PMID: 34820763
-
Comparative polysomnography parameters between narcolepsy type 1/type 2 and idiopathic hypersomnia: A systematic review and meta-analysis.Sleep Med Rev. 2022 Jun;63:101610. doi: 10.1016/j.smrv.2022.101610. Epub 2022 Feb 18. Sleep Med Rev. 2022. PMID: 35278894 Review.
-
The multiple sleep latency test.Handb Clin Neurol. 2019;160:393-403. doi: 10.1016/B978-0-444-64032-1.00026-6. Handb Clin Neurol. 2019. PMID: 31277864 Review.
Cited by
-
Sleep architecture in idiopathic hypersomnia: the influence of age, sex, and body mass index.Sci Rep. 2024 Jul 16;14(1):16407. doi: 10.1038/s41598-024-67203-6. Sci Rep. 2024. PMID: 39013985 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
